Project Grant K08HL171936
Award Date
9/15/24
Completion Date
8/31/29
Dollars Obligated
$287K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nebraska, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $685,884 to the University of North Carolina at Chapel Hill to conduct research on the regulation of coagulation and thrombosis by C1 inhibitor. The research aims to elucidate the molecular mechanisms by which endogenous C1 inhibitor regulates coagulation and venous thrombosis, evaluate the impact of C1 inhibitor deficiency on coagulation...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $829,103 to The Trustees of Columbia University in the City of New York to conduct research on functional coagulation and hemostasis after intracerebral hemorrhage (ICH). The goal is to perform a multimodal assessment of coagulation in ICH patients using traditional clinical assays, contemporary whole blood viscoelastic hemostatic assays,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $563,500.00 to develop and characterize novel complement inhibitors for treating complement-mediated hematologic diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). The award supports a two-phase research project to first develop additional novel complement inhibitors and thoroughly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $234,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to engineer and test "hemostatic red blood cells" (T-RBCs) for the treatment of acute non-compressible hemorrhage. The key objectives are to: 1) engineer T-RBCs that bind to collagen and fibrin to enhance clot formation and stability, 2) perform in vitro testing of the T-RBCs' hemostatic properties, and 3)...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $1,584,308 Project Grant to Northwestern University to conduct research on complementary pathways of necroptosis in recipient and donor lung tissue that drive primary lung allograft dysfunction. The 5-year grant, beginning September 1, 2024, aims to comprehensively understand and pharmacologically target the necroptotic pathways in both the donor and recipient...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $1,253,912 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Thomas Jefferson University (Sidney Kimmel Medical College) to study the role of tRNA- and rRNA-derived short non-coding RNAs (sncRNAs) in the molecular pathogenesis of acute lung injury (ALI). The 4-year project aims to leverage the university's novel "CP-RNA-seq" sequencing...
The University of Nevada, Reno was awarded a $557,649 federal Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on the molecular regulation of beta-2 integrin activation in neutrophil adhesion and inflammation. The research aims to decipher the mechanisms by which the proteins Kindlin-3 and Talin-1 induce activation of beta-2 integrins, which play a key role in neutrophil recruitment and inflammation. The study...